Mitchell E. Daniels, Jr. Governor

Judith A. Monroe, M.D. State Health Commissioner



Vaccine E-Letter # 219

12/22/2006

www.statehealth.in.gov/programs/immunization

In This Issue:	<u>Pg</u> .
ISDH Labs to Move January 2007	
Administering Vaccines: Dose, Route, Site, and Needle Size	

ISDH Labs to Move January 2007

The Indiana State Department of Health (ISDH) Laboratories will be moving in January 2007 from the current location at 635 Barnhill Drive in Indianapolis to a new site located at 550 West 16th Street, Indianapolis, Indiana 46202.

Due to the move, the ISDH Laboratories will not be accepting most <u>routine samples</u> after December 29, 2006. The ISDH Laboratories plan to resume accepting routine samples at the new location on Monday, January 29, 2007. The ISDH Laboratories will continue to provide emergency testing services and accept special types of samples during January 2007. Special samples include samples authorized by the ISDH Immunization program, such as for measles, mumps, and pertussis.

Note that routine samples for influenza and respiratory and other viral cultures and molecular testing of influenza and respiratory viruses is not affected.

If you have questions about the availability of specific Microbiologic analytic services, please contact Tom Cronau, Microbiology Labs at (317) 233-8008.

Administering Vaccines: Dose, Route, Site, and Needle Size

Appropriate vaccine administration is critical to vaccine effectiveness. The recommended site, route, and dosage for each vaccine is based on clinical trials, practical experience, and theoretical considerations. The following chart (on page 2) provides general guidelines for administration of vaccines.

Administration

Route - Administering a vaccine by the recommended route is imperative. Delivering the
vaccine into the appropriate tissue promotes optimal vaccine efficacy and diminishes the risk
of severe local adverse reactions.

Administering Vaccines: Dose, Route, Site, and Needle Size

Vaccines	Dose	Route	Site	Needle Size
Diphtheria, Tetanus, Pertussis (DTaP, DT, Td)	0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers, children & adults	22–25g, 1–2"
Haemophilus influenzae type b (Hib)	0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers & children	22–25g, 1–2"
Hepatitis A (HepA)	≤18 yrs.: 0.5 mL ≥19 yrs.: 1.0 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers, children & adults	22–25g, 1–2"
Hepatitis B (HepB)	≤19 yrs.: 0.5 mL* ≥20 yrs.: 1.0 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers, children & adults	22–25g, 1–2"
Influenza, live attenuated (LAIV)	0.5 mL	Intranasal spray	Administer 0.25 mL dose into each nostril while patient is in an upright position	NA
Influenza, trivalent inactivated (TIV)	6-35 mos: 0.25 mL ≥3 yrs.: 0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers, children & adults	22–25g, 1–2"
Measles, mumps, rubella (MMR)	0.5 mL	SC	Anterolateral fat of thigh: for young children Posterolateral fat of upper arm: for children & adults	23–25g, 5/8"
Meningococcal (Men)	0.5 mL	SC	Anterolateral fat of thigh: for young children Posterolateral fat of upper arm: for children & adults	23–25g, 5/8"
Pneumococcal conjugate (PCV)	0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers & children	22–25g, 1–2"
Pneumococcal polysaccharide (PPV)	0.51	IM	Deltoid	22–25g, 1–2"
		SC	Anterolateral fat of thigh: for young children Posterolateral fat of upper arm: for children & adults	23–25g, 5/8"
Polio, inactivated (IPV)	0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers, children & adults	22–25g, 1-2"
		SC	Anterolateral fat of thigh: for infants & young children Posterolateral fat of upper arm: for children & adults	23–25g, 5/8"
Varicella (Var)	0.5 mL	SC	Anterolateral fat of thigh: for young children Posterolateral fat of upper arm: for children & adults	23–25g, 5/8"

^{*}Persons 11 through 15 years of age may be given Recombivax HB® (Merck) 1.0 mL (adult formulation) on a 2-dose schedule.

Combination Vaccines

DTaP+HepB+IPV (Pediarix TM) DTaP+Hib (Trihibit TM) Hib+HepB (Comvax TM)	0.5 mL	IM	Vastus lateralis: for infants (& toddlers lacking adequate deltoid mass); Deltoid: for toddlers & children	22–25g, 1–2"
HepA+HepB (Twinrix®)	≥18 yrs.: 1.0 mL	IM	Deltoid	22–25g, 1–2"

Please note: Always refer to the package insert included with each biologic for complete vaccine administration information. The Advisory Committee on Immunization Practices (ACIP) statement for the particular vaccine should be reviewed as well.

www.immunize.org/catg.d/p3085.pdf • Item #P3085 (II/03)